• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Savara Inc. (Amendment)

    2/13/24 9:00:11 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email
    SC 13G/A 1 d10965250_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Savara Inc.
    (Name of Issuer)

     

     

    Common Stock, Par Value $0.001 Per Share
    (Title of Class of Securities)

     

     

    805111101
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 805111101    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Caxton Corporation  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      353,441  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      353,441  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      353,441  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     
     

     

     

     

    CUSIP No 805111101    

     

         
    1. NAME OF REPORTING PERSONS  
         
      CDK Associates, L.L.C.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      353,441  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      353,441  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      353,441  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     
     

     

     

     

     

    CUSIP No 805111101    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Bruce S. Kovner  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      353,441  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      353,441  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      353,441  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.3%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

     

     
     

     

     

     

    CUSIP No 805111101    

     

    Item 1. (a). Name of Issuer:  
           
        Savara Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    1717 Langhorne Newton Road, Suite 300

    Langhorne, PA 19047

    United States of America

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Caxton Corporation

    CDK Associates, L.L.C.

    Bruce S. Kovner

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

    CDK Associates, L.L.C.

    c/o Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

    Bruce S. Kovner

    c/o Caxton Corporation

    731 Alexander Road,

    Building 2, Suite 500

    Princeton, New Jersey 08540

     

     

      (c). Citizenship:  
           
       

    Caxton Corporation – Delaware corporation

    CDK Associates, L.L.C. – Delaware limited liability company

    Bruce S. Kovner – United States citizen

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, Par Value $0.001 Per Share  

     

      (e). CUSIP Number:  
           
        805111101  

     

     
     

     

     

     


    Item 3.
    If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    353,441shares deemed beneficially owned by Caxton Corporation

    353,441 shares deemed beneficially owned by CDK Associates, L.L.C.

    353,441 shares deemed beneficially owned by Bruce S. Kovner

     

      (b)   Percent of class:
         
       

    0.3% deemed beneficially owned by Caxton Corporation

    0.3% deemed beneficially owned by CDK Associates, L.L.C.

    0.3% deemed beneficially owned by Bruce S. Kovner

     

      (c)   Number of shares as to which Caxton Corporation has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 353,441 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 353,441 .

     

      Number of shares as to which CDK Associates, L.L.C. has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 353,441 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 353,441 .

     

      Number of shares as to which Bruce S. Kovner has:

     

      (i) Sole power to vote or to direct the vote 0 ,
           
      (ii) Shared power to vote or to direct the vote 353,441 ,
           
      (iii) Sole power to dispose or to direct the disposition of 0 ,
           
      (iv) Shared power to dispose or to direct the disposition of 353,441 .

     

     
     

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

         
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      The shares of the Issuer reported herein are held in the accounts of (i) CDK Associates, L.L.C., an entity for which Caxton Corporation is the Manager, and (ii) another entity for which Caxton Corporation is deemed to have beneficial ownership.  Bruce S. Kovner is the Chairman and sole shareholder of Caxton Corporation. 
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

     

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Caxton Corporation*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      CDK Associates, L.L.C.*
         
      By:  Caxton Corporation, its manager
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
      BRUCE S. KOVNER*
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 13, 2024

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G Amendment No. 2 dated February 13, 2024 relating to the Common Stock, Par Value $0.001 Per Share of Savara Inc., shall be filed on behalf of the undersigned.

      Caxton Corporation
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
         
      CDK Associates, L.L.C.
         
      By:  Caxton Corporation, its manager
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: General Counsel and Chief Compliance Officer
         
         
      BRUCE S. KOVNER
         
       
      By: /s/ Heath N. Weisberg
      Name: Heath N. Weisberg
      Title: Attorney-in-Fact for Bruce S. Kovner
         
      February 13, 2024

     

     

     

     

     
     

    Exhibit B

     

    POWER OF ATTORNEY

     

    Know all by these presents, that the undersigned hereby constitutes and appoints Heath Weisberg, signing singly, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

     

    (1) execute for and on behalf of the undersigned any applications, reports, or documents required or deemed appropriate by the attorney-in-fact to file pursuant to (i) the United States Securities Exchange Act of 1934, as amended, or any rule, or regulation thereunder, including, without limitation, Schedules 13D, 13G, 13F, and 13H, and Forms 3, 4, and 5, (ii) the Securities Act of 1933, as amended, or any rule or regulation thereunder, including, without limitation, Form 144, (iii) the U.S. Commodity Exchange Act, as amended or any rule or regulation thereunder, or (iv) the statutes, rules or regulations of any other domestic or foreign governmental or self-regulatory authority;

     

    (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such applications, reports, or documents;

     

    (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with the applicable statutes, rules and regulations.

     

    This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or otherwise terminated by my death or other event described in section 5-1511 of the New York General Obligations Law.

     

    SIGNATURE AND ACKNOWLEDGMENT:

     

    In Witness Whereof I have hereunto signed my name on the 9th day of May, 2013.

     

    /s/ Bruce Kovner

    Bruce Kovner

     

     
     

     

     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May 2013, before me, the undersigned, personally appeared Bruce Kovner, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

     

    /s/ Cynthia Rosel Rivera

    Notary Public

     

     

    AGENT’S SIGNATURE AND ACKNOWLEDGMENT OF APPOINTMENT:

     

    I, Heath N. Weisberg, have read the foregoing Power of Attorney. I am the person identified therein as agent and attorney-in-fact for the principal named therein.

     

    I acknowledge my legal responsibilities.

     

    /s/ Heath N. Weisberg

    Heath N. Weisberg

     

    STATE OF NEW YORK )  
      ) ss:  
    COUNTY OF NEW YORK )  

     

    On the 9th day of May, 2013, before me, the undersigned, personally appeared Heath N. Weisberg, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

     

     

     

    /s/ Cynthia Rosel Rivera

    Notary Public

     

     

     

     

     

     

     

     

     

    Get the next $SVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    10/20/2025$7.00Overweight
    Wells Fargo
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    5/16/2023$2.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Savara with a new price target

    Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00

    10/20/25 8:03:17 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00

    8/15/25 9:10:16 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00

    5/29/25 8:15:44 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/2/25 7:59:29 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    4/1/25 7:00:04 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Savara Announces Participation in Upcoming Investor Healthcare Conferences

    Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will host one-on-one meetings and participate in fireside chats at two upcoming investor healthcare conferences. Fireside Chats: Guggenheim Emerging Outlook: Biotech Summit February 11th at 12:30pm ET Oppenheimer 36th Annual Healthcare Life Sciences Conference February 25th at 9:20am ET The live webcasts and subsequent replays will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceuti

    2/4/26 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

    -- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$150M of Non-Dilutive Capital for Launch of MOLBREEVI -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), strengthening its balance sheet and liquidity. Under the terms of the amended loan agreement, up to an additional $75 million will become available upon FDA's approval of MOLBREEVI, the Company's investigational therapy in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The loan agreement maturity d

    1/27/26 8:05:00 AM ET
    $HTGC
    $SVRA
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces New Employment Inducement Grant

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 17,500 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 12,500 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listi

    1/16/26 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    SEC Filings

    View All

    Savara Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Savara Inc (0001160308) (Filer)

    1/27/26 8:10:20 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Savara Inc (0001160308) (Filer)

    1/9/26 8:00:33 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Savara Inc.

    144 - Savara Inc (0001160308) (Subject)

    12/18/25 11:17:16 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ramsay David A sold $121,220 worth of shares (20,000 units at $6.06), decreasing direct ownership by 0.78% to 2,533,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    12/19/25 5:00:19 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Lowrance David L covered exercise/tax liability with 62,960 shares and gifted 32,000 shares, decreasing direct ownership by 25% to 286,045 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    12/16/25 5:30:39 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Pauls Matthew covered exercise/tax liability with 195,705 shares and gifted 128,995 shares, decreasing direct ownership by 21% to 1,188,050 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    12/16/25 5:28:36 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

    Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

    9/24/24 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

     Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

    11/10/22 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Resignation of Chief Medical Officer

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

    8/26/22 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Financials

    Live finance-specific insights

    View All

    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

    6/26/24 6:30:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

    6/25/24 8:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/12/24 10:25:33 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care